Monique Nijhuis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/770829/publications.pdf

Version: 2024-02-01

33 papers

2,095 citations

16 h-index 434195 31 g-index

34 all docs

34 docs citations

times ranked

34

3392 citing authors

#	Article	IF	Citations
1	HIV-1 remission following CCR5î"32ſî"32 haematopoietic stem-cell transplantation. Nature, 2019, 568, 244-248.	27.8	447
2	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
3	CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathogens, 2016, 12, e1005701.	4.7	221
4	Rapid and Sensitive Routine Detection of All Members of the Genus <i>Enterovirus </i> in Different Clinical Specimens by Real-Time PCR. Journal of Clinical Microbiology, 2002, 40, 3666-3670.	3.9	155
5	Evidence for HIV-1 cure after CCR5î"32/î"32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV,the, 2020, 7, e340-e347.	4.7	151
6	A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Medicine, 2007, 4, e36.	8.4	146
7	A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Scientific Reports, 2017, 7, 41968.	3.3	110
8	Digital PCR as a tool to measure HIV persistence. Retrovirology, 2018, 15, 16.	2.0	66
9	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Annals of Internal Medicine, 2018, 169, 674.	3.9	59
10	Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Î"32 Homozygous Stem Cells. Clinical Infectious Diseases, 2019, 68, 684-687.	5.8	42
11	Failure of Treatment with Firstâ€Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V. Journal of Infectious Diseases, 2009, 200, 698-709.	4.0	32
12	Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients. PLoS ONE, 2014, 9, e110749.	2.5	32
13	Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. PLoS ONE, 2015, 10, e0132430.	2.5	26
14	Characterization of HIV-1 Infection in Microglia-Containing Human Cerebral Organoids. Viruses, 2022, 14, 829.	3.3	24
15	Complex T-Cell Receptor Repertoire Dynamics Underlie the CD8+T-Cell Response to HIV-1. Journal of Virology, 2015, 89, 110-119.	3.4	23
16	Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance. Retrovirology, 2018, 15, 1.	2.0	23
17	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Science Translational Medicine, 2020, 12, .	12.4	17
18	Development of sensitive dd <scp>PCR</scp> assays to reliably quantify the proviral <scp>DNA</scp> reservoir in all common circulating <scp>HIV</scp> subtypes and recombinant forms. Journal of the International AIDS Society, 2018, 21, e25185.	3.0	16

#	Article	IF	CITATIONS
19	Human microglial models to study HIV infection and neuropathogenesis: a literature overview and comparative analyses. Journal of NeuroVirology, 2022, 28, 64-91.	2.1	15
20	HIV protease resistance and viral fitness. Current Opinion in HIV and AIDS, 2007, 2, 108-115.	3.8	13
21	All-printed cell counting chambers with on-chip sample preparation for point-of-care CD4 counting. Biosensors and Bioelectronics, 2018, 117, 659-668.	10.1	13
22	High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients. Clinical Infectious Diseases, 2017, 64, 1092-1097.	5.8	11
23	Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model. Retrovirology, 2014, 11, 113.	2.0	10
24	Novel mechanisms of HIV protease inhibitor resistance. Current Opinion in HIV and AIDS, 2008, 3, 627-632.	3.8	9
25	Robust regression methods for real-time polymerase chain reaction. Analytical Biochemistry, 2015, 480, 34-36.	2.4	7
26	Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. Journal of Antimicrobial Chemotherapy, 2015, 70, 573-580.	3.0	7
27	Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses. Journal of the International AIDS Society, 2014, 17, 19755.	3.0	6
28	A public–private partnership model for COVID-19 diagnostics. Nature Biotechnology, 2021, 39, 1182-1184.	17.5	4
29	In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center. Open Forum Infectious Diseases, 2022, 9, ofab553.	0.9	4
30	Short Communication: <i>In Vitro</i> Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine. AIDS Research and Human Retroviruses, 2015, 31, 851-858.	1.1	3
31	An inkjet-printed polysaccharide matrix for on-chip sample preparation in point-of-care cell counting chambers. RSC Advances, 2020, 10, 18062-18072.	3.6	3
32	A trip down memory lane with Retrovirology. Retrovirology, 2019, 16, 22.	2.0	0
33	Graft Versus HIV-1 Reservoir Effect after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1234-1234.	1.4	0